Reduced Risk of Reinfection with SARS-CoV-2 After CO May–June 2021

Morbidity and Mortality Weekly Report 70, 1081-1083

DOI: 10.15585/mmwr.mm7032e1

Citation Report

#	Article	IF	CITATIONS
6	Vaccinating people who have had covid-19: why doesn't natural immunity count in the US?. BMJ, The, 2021, 374, n2101.	6.0	28
7	Towards Al-Enabled Multimodal Diagnostics and Management of COVID-19 and Comorbidities in Resource-Limited Settings. Informatics, 2021, 8, 63.	3.9	11
8	Natural vs. Vaccine Mediated COVID-19 Immunity Scientific Justification to Mandate Vaccination of Recovered Healthcare Workers. DHR Proceedings, 2021, 1, 15-16.	0.8	0
9	Results of Serosurveillance and Forecasting the Third Wave of COVID-19 in an Industrial District in India. Cureus, 2021, 13, e18097.	0.5	0
11	A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection. Evaluation and the Health Professions, 2021, 44, 327-332.	1.9	79
12	Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 43-54.	1.3	7
13	The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus, 2021, 11, 20210008.	3.0	24
15	SARS-CoV-2 Reinfection Is a New Challenge for the Effectiveness of Global Vaccination Campaign: A Systematic Review of Cases Reported in Literature. International Journal of Environmental Research and Public Health, 2021, 18, 11001.	2.6	14
16	COVID reinfections likely within one or two years, models propose. Nature, 2021, , .	27.8	3
17	Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. Cureus, 2021, 13, e19102.	0.5	50
18	Reinfection and Breakthrough Infection of SARS-CoV-2: An Emerging Challenge That Is Threatening Our World. Infectious Diseases & Immunity, 2022, 2, 29-33.	0.6	3
20	Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. Emerging Infectious Diseases, 2022, 28, 36-44.	4.3	19
21	Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe, The, 2022, 3, e52-e61.	7.3	436
22	Spatial Analysis of COVID-19 Vaccination: A Scoping Review. International Journal of Environmental Research and Public Health, 2021, 18, 12024.	2.6	18
23	Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection Associates With Unstable Housing and Occurs in the Presence of Antibodies. Clinical Infectious Diseases, 2022, 75, e208-e215.	5.8	16
24	COVID-19 Delta Variant: Perceptions, Worries, and Vaccine-Booster Acceptability among Healthcare Workers. Healthcare (Switzerland), 2021, 9, 1566.	2.0	57
26	Management of post-acute COVID-19 patients in geriatric rehabilitation: EuGMS guidance. European Geriatric Medicine, 2022, 13, 291-304.	2.8	16
27	Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Translational Research, 2022, 241, 1-12.	5.0	15

	CITATION R	CITATION REPORT	
# 28	ARTICLE Covid-19 Vaccine Effectiveness in New York State. New England Journal of Medicine, 2022, 386, 116-127.	IF 27.0	Citations 233
30	Evaluation of two rapid lateral flow tests and two surrogate ELISAs for the detection of SARS-CoV-2 specific neutralizing antibodies. SSRN Electronic Journal, 0, , .	0.4	2
31	Detection of significant antiviral drug effects on COVID-19 using viral load and PCR-positive rate in randomized controlled trials. Translational and Regulatory Sciences, 2021, 3, 85-88.	0.2	0
33	Public Perceptions of Current COVID-19 Vaccinations. Results of a Pilot Survey. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962110669.	1.7	4
34	Risk for Reinfection After SARS-CoV-2: A Living, Rapid Review for American College of Physicians Practice Points on the Role of the Antibody Response in Conferring Immunity Following SARS-CoV-2 Infection. Annals of Internal Medicine, 2022, 175, 547-555.	3.9	38
35	SARS-CoV-2 Reinfections: Overview of Efficacy and Duration of Natural and Hybrid Immunity. SSRN Electronic Journal, 0, , .	0.4	3
36	Different decay of antibody response and VOC sensitivity in naÃ⁻ve and previously infected subjects at 15Âweeks following vaccination with BNT162b2. Journal of Translational Medicine, 2022, 20, 22.	4.4	11
37	Necessity of Coronavirus Disease 2019 (COVID-19) Vaccination in Persons Who Have Already Had COVID-19. Clinical Infectious Diseases, 2022, 75, e662-e671.	5.8	59
38	SARS-CoV-2 Variants, Vaccines, and Host Immunity. Frontiers in Immunology, 2021, 12, 809244.	4.8	176
39	SARS-CoV-2 Reinfection Rate and Estimated Effectiveness of the Inactivated Whole Virion Vaccine BBV152 Against Reinfection Among Health Care Workers in New Delhi, India. JAMA Network Open, 2022, 5, e2142210.	5.9	48
40	What Is the Antibody Response and Role in Conferring Natural Immunity After SARS-CoV-2 Infection? Rapid, Living Practice Points From the American College of Physicians (Version 2). Annals of Internal Medicine, 2022, , .	3.9	1
41	COVID-19 Cases and Hospitalizations by COVID-19 Vaccination Status and Previous COVID-19 Diagnosis — California and New York, May–November 2021. Morbidity and Mortality Weekly Report, 2022, 71, 125-131.	15.1	119
42	Vaccine Effectiveness Against COVID19-Infection and Onward Transmission by Variant of Concern and Time Since Vaccination, Belgian Contact Tracing, 2021. SSRN Electronic Journal, 0, , .	0.4	3
43	Persistence of Anti-SARS-CoV-2 Antibodies in Long Term Care Residents Over Seven Months After Two COVID-19 Outbreaks. Frontiers in Immunology, 2021, 12, 775420.	4.8	8
44	Effect of vaccination on SARS-CoV-2 reinfection risk: a case-control study in the Republic of Cyprus. Public Health, 2022, 204, 84-86.	2.9	1
45	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. American Journal of Epidemiology, 2022, 191, 800-811.	3.4	53
46	Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology, 2022, 7, eabn8014.	11.9	220
47	Sexual dimorphism in COVID-19: potential clinical and public health implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 221-230.	11.4	78

#	Article	IF	CITATIONS
48	Post ovidâ€19â€vaccination adverse events and healthcare utilization among individuals with or without previous SARS oVâ€2 infection. Journal of Internal Medicine, 2022, 291, 864-869.	6.0	21
49	Cost-effective proactive testing strategies during COVID-19 mass vaccination: A modelling study. The Lancet Regional Health Americas, 2022, 8, 100182.	2.6	10
50	Modelling epidemic spreading in structured organisations. Physica A: Statistical Mechanics and Its Applications, 2022, 592, 126875.	2.6	5
51	Study on the Refusal of Vaccination against COVID-19 in Romania. Vaccines, 2022, 10, 261.	4.4	22
52	Cellular Responses to Membrane and Nucleocapsid Viral Proteins Are Also Boosted After SARS-CoV-2 Spike mRNA Vaccination in Individuals With Either Past Infection or Cross-Reactivity. Frontiers in Microbiology, 2021, 12, 812729.	3.5	5
53	Evaluation of Two Rapid Lateral Flow Tests and Two Surrogate ELISAs for the Detection of SARS-CoV-2 Specific Neutralizing Antibodies. Frontiers in Medicine, 2022, 9, 820151.	2.6	11
54	Post-Vaccination SARS-CoV-2 Infections among Health Workers at the University Hospital of Verona, Italy: A Retrospective Cohort Survey. Vaccines, 2022, 10, 272.	4.4	24
56	SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environmental Research, 2022, 209, 112911.	7.5	181
58	SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History. Microbiology Spectrum, 2022, 10, e0226221.	3.0	5
59	An Opportunity to Understand Concerns about COVID-19 Vaccination: Perspectives from EMS Professionals. Vaccines, 2022, 10, 380.	4.4	3
60	Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection. New England Journal of Medicine, 2022, 386, 1207-1220.	27.0	452
61	SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets. Journal of Virology, 2022, 96, JVI0179121.	3.4	23
62	Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity. Frontiers in Immunology, 2022, 13, 830433.	4.8	12
63	Persistent Antibody Responses Up to 18 Months After Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of Infectious Diseases, 2022, 226, 1224-1230.	4.0	13
64	Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19. New England Journal of Medicine, 2022, 386, 1221-1229.	27.0	98
65	Outcomes After SARS-CoV-2 Vaccination Among Children With a History of Multisystem Inflammatory Syndrome. JAMA Network Open, 2022, 5, e224750.	5.9	7
66	Demystifying mRNA vaccines: an emerging platform at the forefront of cryptic diseases. RNA Biology, 2022, 19, 386-410.	3.1	19
67	Reâ€infection in COVIDâ€19: Do we exaggerate our worries?. European Journal of Clinical Investigation, 2022, 52, e13767.	3.4	11

#	Article	IF	CITATIONS
69	Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. Journal of Medical Virology, 2022, 94, 3416-3420.	5.0	41
70	It is not too late to achieve global covid-19 vaccine equity. BMJ, The, 2022, 376, e070650.	6.0	62
71	Low Levels of Neutralizing Antibodies After Natural Infection With Severe Acute Respiratory Syndrome Coronavirus 2 in a Community-Based Serological Study. Open Forum Infectious Diseases, 2022, 9, ofac055.	0.9	4
72	Post–COVID-19 syndrome and humoral response association after 1Âyear in vaccinated and unvaccinated patients. Clinical Microbiology and Infection, 2022, 28, 1140-1148.	6.0	35
73	Couples and COVID-19 vaccination: Frequency and reasons for discordance. Vaccine, 2022, 40, 1913-1917.	3.8	3
75	A Clinician's Obligation to be Vaccinated: Four Arguments that Establish a Duty for Healthcare Professionals to be Vaccinated Against COVID-19. Journal of Bioethical Inquiry, 2022, 19, 451-465.	1.5	5
76	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. Lancet Infectious Diseases, The, 2022, 22, 791-801.	9.1	84
77	Vaccination and natural immunity: Advantages and risks as a matter of public health policy. The Lancet Regional Health Americas, 2022, 8, 100242.	2.6	1
78	<i>Notes from the Field: </i> SARS-CoV-2 Omicron Variant Infection in 10 Persons Within 90 Days of Previous SARS-CoV-2 Delta Variant Infection — Four States, October 2021–January 2022. Morbidity and Mortality Weekly Report, 2022, 71, 524-526.	15.1	8
79	Cellular Immune Response in Patients Immunized with Three Vaccine Doses of Different Vaccination Schemes Authorized by the Chilean Ministry of Health in January 2022. Life, 2022, 12, 534.	2.4	3
80	Hybrid immunity against COVID-19 in different countries with a special emphasis on the Indian scenario during the Omicron period. International Immunopharmacology, 2022, 108, 108766.	3.8	12
83	Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices. Indian Pediatrics, 2022, 59, 51-57.	0.4	10
84	The Effectiveness of Post-Vaccination and Post-Infection Protection in the Hospital Staff of Three Prague Hospitals: A Cohort Study of 8-Month Follow-Up from the Start of the COVID-19 Vaccination Campaign (COVANESS). Vaccines, 2022, 10, 9.	4.4	11
85	A 48-Year-Old Immunocompetent Female Resident of Southern Florida with Confirmed Reinfection with P.1 (Gamma) Variant of SARS-CoV-2. American Journal of Case Reports, 2022, 23, e935329.	0.8	0
87	Vaccine-induced immune responses against SARS-CoV-2 infections. Exploration of Immunology, 0, , 356-373.	0.3	0
88	An update on host immunity correlates and prospects of re-infection in COVID-19. International Reviews of Immunology, 2022, 41, 367-392.	3.3	9
91	Vaccination and Covid 19 Infections. Medicina Interna (Bucharest, Romania: 1991), 2022, 19, 97-105.	0.0	0
92	Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray. Frontiers in Immunology, 2022, 13, 817345.	4.8	5

#	Article	IF	CITATIONS
94	Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. Viruses, 2022, 14, 802.	3.3	30
95	Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021. Vaccine, 2022, 40, 3027-3037.	3.8	18
96	Comparing COVID-19-related hospitalization rates among individuals with infection-induced and vaccine-induced immunity in Israel. Nature Communications, 2022, 13, 2202.	12.8	13
97	Barriers to COVID-19 Vaccines and Strategies to Improve Acceptability and Uptake. Journal of Pharmacy Practice, 2023, 36, 900-904.	1.0	12
98	Coronavirus Disease 2019 (COVID-19) Vaccination for Children: Position Statement of Indian Academy of Pediatrics Advisory Committee on Vaccination and Immunization Practices Indian Pediatrics, 2021, , .	0.4	2
99	Making waves: Wastewater surveillance of SARS-CoV-2 in an endemic future. Water Research, 2022, 219, 118535.	11.3	37
100	Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection. BMC Medicine, 2022, 20, 181.	5.5	10
101	COVID-19 Booster Vaccination Hesitancy in the United States: A Multi-Theory-Model (MTM)-Based National Assessment. Vaccines, 2022, 10, 758.	4.4	24
102	Enhancing resilience in construction against infectious diseases using stochastic multi-agent approach. Automation in Construction, 2022, 140, 104315.	9.8	5
103	The Primacy of Moringa (Moringa oleifera Lam.) in Boosting Nutrition Status and Immunity Defence Amidst the COVID-19 Catastrophe: A Perspective. Phyton, 2022, 91, 1831-1858.	0.7	1
104	Understanding "Hybrid Immunity― Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. Clinical Infectious Diseases, 2023, 76, e439-e449.	5.8	23
105	Trajectory patterns of SARS-CoV-2 neutralising antibody response in convalescent COVID-19 patients. Communications Medicine, 2022, 2, .	4.2	2
106	Current advancements and future prospects of COVID-19 vaccines and therapeutics: a narrative review. , 2022, 10, 251513552210975.	2.3	6
108	Clinical Characteristics and Outcomes of Patients With SARS-CoV-2 Reinfection. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2022, 6, 361-372.	2.4	4
109	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. Russian Pediatric Journal, 2022, 25, 139-146.	0.2	0
110	A Primer on <scp>Post OVID</scp> â€19 Conditions and Implications for Clinical Pharmacists. JACCP Journal of the American College of Clinical Pharmacy, 0, , .	1.0	0
111	Association of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination or a Prior Positive Test Result in Adolescents during the Delta Variant Surge in Kentucky. Journal of Pediatrics, 2022, 248, 119-121.	1.8	3
112	Are we suffering from the Peltzman effect? Risk perception among recovered and vaccinated people during the COVID-19 pandemic in Israel. Public Health, 2022, 209, 19-22.	2.9	7

.,		15	Circination
#	ARTICLE	IF	CHATIONS
114	Among New York City Adults, July 2021–November 2021. Clinical Infectious Diseases, 2023, 76, e469-e476.	5.8	9
115	Public Perception of SARS-CoV-2 Vaccines Among Psoriasis Patients in Social Media: Content, Sentiment, and Engagement Analysis. Journal of Psoriasis and Psoriatic Arthritis, 0, , 247553032211100.	0.7	0
116	Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.	2.2	11
117	Booster Vaccination Decreases 28-Day All-Cause Mortality of the Elderly Hospitalized Due to SARS-CoV-2 Delta Variant. Vaccines, 2022, 10, 986.	4.4	7
118	SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes. Journal of Infection and Public Health, 2022, 15, 773-780.	4.1	11
119	Horny for COVID. Extrapolation, 2022, 63, 55-73.	0.2	0
120	Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. PLoS ONE, 2022, 17, e0264298.	2.5	0
121	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS ONE, 2022, 17, e0270801.	2.5	18
122	Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet, The, 2022, 400, 535-538.	13.7	27
123	Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. BMC Infectious Diseases, 2022, 22, .	2.9	6
124	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
125	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	3.5	10
126	SARS-CoV-2 Antibody Response against Mild-to-Moderate Breakthrough COVID-19 in Home Isolation Setting in Thailand. Vaccines, 2022, 10, 1131.	4.4	3
127	<scp>COVID</scp> â€19 and plasma cells: Is there longâ€lived protection?*. Immunological Reviews, 2022, 309, 40-63.	6.0	26
128	Two cases of acute respiratory failure following <scp>SARSâ€CoV</scp> â€2 vaccination in post― <scp>COVID</scp> â€19 pneumonia. Respirology Case Reports, 2022, 10, .	0.6	2
129	Risk and severity of SARS-CoV-2 reinfections during 2020–2022 in Vojvodina, Serbia: A population-level observational study. Lancet Regional Health - Europe, The, 2022, 20, 100453.	5.6	47
130	Protection Against the Omicron Variant Offered by Previous Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Retrospective Cohort Study. Clinical Infectious Diseases, 2023, 76, e142-e147.	5.8	8
131	Effectiveness Associated With Vaccination After COVID-19 Recovery in Preventing Reinfection. JAMA Network Open, 2022, 5, e2223917.	5.9	19

#	Article	IF	CITATIONS
132	Reinfection with SARS oVâ€2 in general population, South Korea; nationwide retrospective cohort study. Journal of Medical Virology, 2022, 94, 5589-5592.	5.0	15
133	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
134	Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria. Viruses, 2022, 14, 1642.	3.3	4
135	High SARS-CoV-2 Seroprevalence and Rapid Neutralizing Antibody Decline among Agricultural Workers in Rural Guatemala, June 2020–March 2021. Vaccines, 2022, 10, 1160.	4.4	1
136	Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia. Frontiers in Medicine, 0, 9, .	2.6	4
137	Effects of vaccination, new SARS-CoV-2 variants and reinfections on post-COVID-19 complications. Frontiers in Public Health, 0, 10, .	2.7	5
138	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. Frontiers in Public Health, 0, 10, .	2.7	70
139	Development of robust, indigenous ELISA for detection of IgG antibodies against CoV-2ÂN and S proteins: mass screening. Applied Microbiology and Biotechnology, 0, , .	3.6	2
140	Rapid Increase in Suspected SARS-CoV-2 Reinfections, Clark County, Nevada, USA, December 2021. Emerging Infectious Diseases, 2022, 28, 1977-1981.	4.3	8
141	Epidemiological assessment of SARS-CoV-2 reinfection. International Journal of Infectious Diseases, 2022, 123, 9-16.	3.3	13
142	COVID-19 in patients with B cell immune deficiency. Journal of Immunological Methods, 2022, 510, 113351.	1.4	1
143	An assessment of COVID-19 infection after vaccination amongst health-care workers at a tertiary care centre, kodagu, Karnataka. Journal of Medical Evidence, 2022, .	0.1	0
144	Covid-19 vaccine hesitancy: Text mining, sentiment analysis and machine learning on COVID-19 vaccination Twitter dataset. Expert Systems With Applications, 2023, 212, 118715.	7.6	65
145	Microbiological and Clinical Findings of SARS-CoV-2 Infection after 2 Years of Pandemic: From Lung to Gut Microbiota. Diagnostics, 2022, 12, 2143.	2.6	4
146	Effectiveness of Booster Doses of the SARS-CoV-2 Inactivated Vaccine KCONVAC against the Mutant Strains. Viruses, 2022, 14, 2016.	3.3	8
148	Acceptance of coronavirus disease 2019 vaccination among postpartum women during delivery hospitalization. Journal of Maternal-Fetal and Neonatal Medicine, 0, , 1-4.	1.5	0
149	Public knowledge and attitude towards COVID-19 vaccines, implementation of preventive measures following vaccination, and perceived stress during the COVID-19 pandemic: A cross-sectional study in Jordan. Electronic Journal of General Medicine, 2022, 19, em421.	0.7	1
150	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. Frontiers in Immunology, 0, 13, .	4.8	5

#	Article	IF	CITATIONS
151	COVID-19 Vaccination Intention and Factors Associated with Hesitance and Resistance in the Deep South: Montgomery, Alabama. Tropical Medicine and Infectious Disease, 2022, 7, 331.	2.3	1
153	Mucosal and Systemic Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Determined by Severity of Primary Infection. MSphere, 2022, 7, .	2.9	3
154	Likelihood of COVID-19 reinfection in an urban community cohort in Massachusetts. , 2022, 1, 100057.		0
155	Epidemiology and Clinical Presentation of COVID-19 in Older Adults. Infectious Disease Clinics of North America, 2023, 37, 1-26.	5.1	10
156	COVID-19 vaccines reduce the risk of SARS-CoV-2 reinfection and hospitalization: Meta-analysis. Frontiers in Medicine, 0, 9, .	2.6	16
157	SARS-CoV-2 neutralizing antibody response in vaccinated and non-vaccinated hospital healthcare workers with or without history of infection. Microbes and Infection, 2022, , 105077.	1.9	2
158	Smoking cessation in the elderly as a sign of susceptibility to symptomatic COVID-19 reinfection in the United States. Frontiers in Public Health, 0, 10, .	2.7	2
159	Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Medicine, 2022, 19, e1004037.	8.4	28
160	How Protective are Antibodies to SARS-CoV-2, the Main Weapon of the B-Cell Response?. Stem Cell Reviews and Reports, 0, , .	3.8	2
161	Association of dual COVID-19 and seasonal influenza vaccination with COVID-19 infection and disease severity. Vaccine, 2023, 41, 875-878.	3.8	9
162	B-Cell Responses to Sars-Cov-2 mRNA Vaccines. Pathogens and Immunity, 2022, 7, 93-119.	3.1	0
163	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. Journal of Taibah University Medical Sciences, 2023, 18, 600-638.	0.9	1
165	Antibody response to receptor-binding domain of SARS-CoV-2 spike protein following vaccination and natural infection with SARS-CoV-2. IMC Journal of Medical Science, 0, , 1-7.	0.4	0
166	Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, January–June 2021. Journal of Infectious Diseases, 0, , .	4.0	0
167	Current and Emerging Knowledge in COVID-19. Radiology, 2023, 306, .	7.3	30
168	COVID-19 Risk Compensation? Examining Vaccination Uptake among Recovered and Classification of Breakthrough Cases. Healthcare (Switzerland), 2023, 11, 58.	2.0	2
169	Factors Associated with Intention to Vaccinate Children 0-11 Years of Age Against COVID-19. Journal of the American Board of Family Medicine, 2022, 35, 1174-1178.	1.5	1
171	Dynamics of Antibody Responses after Asymptomatic and Mild to Moderate SARS-CoV-2 Infections: Real-World Data in a Resource-Limited Country. Tropical Medicine and Infectious Disease, 2023, 8, 185.	2.3	0

#	Article	IF	Citations
172	Understanding the barriers and facilitators of vaccine hesitancy towards the COVID-19 vaccine in healthcare workers and healthcare students worldwide: An Umbrella Review. PLoS ONE, 2023, 18, e0280439.	2.5	11
173	Early Career Occupational Therapists' Experiences during the COVID-19 Pandemic. Occupational Therapy in Health Care, 0, , 1-20.	0.3	1
174	COVID-19 Vaccination in Paediatric Population of India: Current Status, Trends, Challenges and Recommendations. Journal of Pure and Applied Microbiology, 2023, 17, 69-79.	0.9	0
175	SARS-CoV-2-Neutralizing Antibody Response and Correlation of Two Serological Assays with Microneutralization. Vaccines, 2023, 11, 590.	4.4	3
176	Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. Frontiers in Public Health, 0, 11, .	2.7	7
177	Diseminasi hasil riset determinan kecemasan dan depresi pasca vaksinasi Covid-19. KACANEGARA Jurnal Pengabdian Pada Masyarakat, 2023, 6, 123.	0.3	0
178	Political variations in pandemic lifestyles and COVID-19 vaccination by age cohort in the United States. Preventive Medicine, 2023, 172, 107525.	3.4	1
179	Outcomes associated with SARS-CoV-2 reinfection in individuals with natural and hybrid immunity. Journal of Infection and Public Health, 2023, 16, 1262-1268.	4.1	1
180	Agent-based epidemics simulation to compare and explain screening and vaccination prioritization strategies. Simulation, 2024, 100, 335-355.	1.8	1
181	Real-world effectiveness of COVID-19 vaccines: A retrospective cohort study of vaccinated individuals in Jazan, Saudi Arabia. Journal of Infection and Public Health, 2023, , .	4.1	2
182	The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice. Vaccines, 2023, 11, 1181.	4.4	7
184	"Boosting―Surveillance for a More Impactful Public Health Response During Protracted and Evolving Infectious Disease Threats: Insights From the COVID-19 Pandemic. Health Security, 2023, 21, S47-S55.	1.8	2
185	Rationale for combined therapies in severe-to-critical COVID-19 patients. Frontiers in Immunology, 0, 14, .	4.8	0
186	Antibody titers of individuals vaccinated forÂCOVID-19: A systematic review. Journal of Biosciences, 2023, 48, .	1.1	0
187	Determinants of risk factors for COVID-19 transmission in densely populated areas: Insights from the first wave of the pandemic. Electronic Journal of General Medicine, 2023, 20, em531.	0.7	2
188	Impact of prior COVID-19 infection on perceptions about the benefit and safety of COVID-19 vaccines. American Journal of Infection Control, 2024, 52, 125-128.	2.3	2
189	Risk Factors Related to COVID-19 Reinfection and Fatality During the Omicron (BA.1/BA.2) Period in Korea. Journal of Korean Medical Science, 2023, 38, .	2.5	2
190	SARS-CoV-2 Reinfection Risk in Persons with HIV, Chicago, Illinois, USA, 2020–2022. Emerging Infectious Diseases, 2023, 29, .	4.3	0

#	Article	IF	CITATIONS
191	Relative Risk of COVID-19 Reinfection by Demographic and Vaccination Factors During the Period March 2020-October 2022. Journal of Community Health, 0, , .	3.8	0
192	The politics of COVID-19: Differences between U.S. red and blue states in COVID-19 regulations and deaths. Health Policy OPEN, 2023, 5, 100107.	1.5	0
193	êµë,´ì¼2"ë;œë,~ë°"ì•러ìŠ&°ì—¼ì¦•19 재ê°ì—¼ ì¶"ì•ì,¬ë;€ î~"황 ë°•ì~ë°©ì¹ì⊄… 효과 í‰ê°€. , 2023, 16, 1504	-1520.	1
194	Low Risk of SARS-CoV-2 Reinfection for Fully or Boosted mRNA Vaccinated Subjects in Sicily: A Population-Based Study Using Real-World Data. Vaccines, 2023, 11, 1757.	4.4	0
195	Risk Factors Contributing to Reinfection by SARS-CoV-2: A Systematic Review. Advances in Respiratory Medicine, 2023, 91, 560-570.	1.0	0
196	Transmission of COVID-19 in the presence of single-dose and double-dose vaccines with hesitancy: mathematical modeling and optimal control analysis. Frontiers in Applied Mathematics and Statistics, 0, 9, .	1.3	0
198	One dose versus two doses of COVIDâ€19 vaccine for the prevention of breakthrough infections among people previously infected with SARSâ€Covâ€2. Journal of Medical Virology, 2024, 96, .	5.0	0
199	Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population. Nature Communications, 2024, 15, .	12.8	0
200	Safety and efficiency of COVID-19 vaccine in North Africa. Human Vaccines and Immunotherapeutics, 2024, 20, .	3.3	0
201	Long-Term Dynamic Changes in Hybrid Immunity over Six Months after Inactivated and Adenoviral Vector Vaccination in Individuals with Previous SARS-CoV-2 Infection. Vaccines, 2024, 12, 180.	4.4	0
202	Exploring the reported adverse effects of COVID-19 vaccines among vaccinated Arab populations: a multi-national survey study. Scientific Reports, 2024, 14, .	3.3	0